CrossrefInfokarte
Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis
International Journal of Urology · 2026-11 · 33 (11)
DOI: 10.1111/iju.70699 ↗Abstract
Kein Abstract verfügbar.
EUVIMED